
-
Allogene Therapeutics NasdaqGS:ALLO Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Location: 210 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://allogene.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
66.98M
Cash
280M
Avg Qtr Burn
-49.33M
Short % of Float
17.48%
Insider Ownership
17.21%
Institutional Own.
81.20%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cemacabtagene Ansegedleucel (cema-cel) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
ALLO-647 (Anti-CD52 mAb) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
ALLO-316 (CD70) Details Clear cell renal cell carcinoma (ccRCC) | Phase 1b Data readout | |
ALLO-715 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update | |
Cemacabtagene ansegedleucel, or cema-cel [ALLO-501A (CD19)] Details Cancer, Chronic lymphocytic leukemia | Phase 1 Update | |
ALLO-605 (BCMA) Details Multiple myeloma, Cancer | Phase 1 Update | |
ALLO-329 [CD19/CD70 Dual CAR] Details Autoimmune disease | Phase 1 Initiation |